Equipment for nuclear medicine (global market)

Nuclear medicine is a section of clinical medicine that is engaged in the use of radionuclide pharmaceuticals in diagnosis and treatment. Among the equipment, diagnostics mainly use single-photon emission computed tomographs (SPECT, capture gamma radiation) and positron emission tomographs (PET scanners), and radioiodotherapy prevails in treatment.

2016: Market volume of $4.7 billion

In October 2016, the analytical company MarketsandMarkets published some results of a study of the global market for equipment for nuclear medicine and radiopharmaceuticals. Its volume, as experts predict, will increase by more than half in five years.

According to MarketsandMarkets expectations, in 2016, sales of equipment for radionuclide diagnostics and treatment on a global scale will reach $4.7 billion, and by 2021 this figure will increase to $7.3 billion. Thus, the market under consideration will show an average annual growth of 9.3%.

In 2016, the market for equipment for nuclear medicine will amount to $4.7 billion, forecast in MarketsandMarkets

According to analysts, the main driver of the market recovery is the growing use of equipment such as OFECT and PET, as well as advanced cancer treatments with radiopharmaceuticals and alpha-radioimmunotherapy. In addition, the demand for equipment for nuclear medicine is increasing as a result of an increase in the number of cases of cancer and heart disease.

Researchers attributed to the factor restraining the development of the market that the use of modern and safest radiopharmaceuticals is limited by their high cost and the difficulties associated with the transportation and storage of radionuclides with a short half-life.

In addition, strict market regulations and the popularity of traditional diagnostic methods have a negative impact on the sales of nuclear medicine devices and radiopharmaceuticals.^[1]

Notes